Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 8, 2017 and accepted by EDGAR at Nov 8, 2017, 17:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-07-01 to 2017-09-30 | $943.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$839.3k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-07-01 to 2017-09-30 | $8.9k | us-gaap:InterestExpense |
| Interest expense | 9 months2017-01-01 to 2017-09-30 | $70.6k | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $3.8k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $4.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$743.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$7.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | −$0.45 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | −$0.45 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 15,867,159 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 15,973,737 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | −$98.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $172.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2017-01-01 to 2017-09-30 | $2.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-09-30 | $42.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $66.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $90.4m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $15.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $25.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-09-30 | $65.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-17-011224. Last ingested by Listed: Nov 11, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.